High-dose melphalan plus bortezomib for multiple myeloma patients as a conditioning of auto-PBSCT
Phase 2
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000005582
- Lead Sponsor
- FBMTG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)nonsecreatry MM or PCL 2)patinets underwent HSCT previously 3)> grade2 PN 4)HIV,HBV,HCV 5)patients suffering from other active cancers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the efficacy and safety of high-dose melphalan plus bortezomib for MM patients as a conditioning of auto-PBSCT.
- Secondary Outcome Measures
Name Time Method 1) ORR at day 100 2) PFS at 1-yr 3) OS at 1-yr